GLP ‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy
Clinical and Experimental Pharmacology and Physiology · 2024
DOI: 10.1111/1440-1681.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2024. Verfasst von Tingting Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China. Hauptthemen laut MEDLINE: Liraglutide, NF-E2-Related Factor 2, Diabetic Nephropathies, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Fujian Provincial Natural Science Foundation of China, Startup Fund for scientific research of Fujian Medical University, Scientific and Technological Major Special Project of Fujian Provincial Health Commission.
Abstract (Originalsprache)
Diabetic nephropathy (DN) is a severe renal disorder that arises as a complication of diabetes. Liraglutide, an analogue of a glucagon‐like peptide 1 (GLP‐1) receptor agonist, has been shown to decrease diabetes‐caused renal damage. Nevertheless, the complete understanding of the roles and mechanism remains unclear. In our study, diabetic rat models were created through a single intraperitoneal injection of streptozotocin (STZ). The level of fasting blood glucose, 24‐h urine protein, serum creatinine (Scr) and blood urea nitrogen (BUN) were assessed. Periodic acid‐Schiff (PAS) staining was applied to examine the pathological changes in renal tissues. Reactive oxygen species (ROS) formation was measured via dichloro‐dihydro‐fluorescein diacetate (DCFH‐DA) probes. Western blot was conducted to examine the levels of oxidative stress‐related and extracellular matrix (ECM)‐associated proteins. The nuclear translocation of NRF2 was investigated through immunofluorescence and Western blot assays. We demonstrated that liraglutide attenuated DN‐induced oxidative stress and ECM deposition in vitro and in vivo. Liraglutide exerted a reno‐protective effect by promoting nuclear translocation of NRF2 in mesangial cells. ML385, an NRF2 inhibitor, counteracted the beneficial impact of liraglutide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
- Department of Cardiovascular Medicine, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China.
Förderung
- Fujian Provincial Natural Science Foundation of China
- Startup Fund for scientific research of Fujian Medical University
- Scientific and Technological Major Special Project of Fujian Provincial Health Commission
Zitieren
APA
Lin, T., Zhang, Y., Wei, Q., & Huang, Z. (2024). GLP ‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70003
Vancouver
Lin T, Zhang Y, Wei Q, Huang Z. GLP ‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy. Clinical and Experimental Pharmacology and Physiology. 2024. doi:10.1111/1440-1681.70003
BibTeX
@article{Lin2024,
author = {Lin, Tingting and Zhang, Yuze and Wei, Qifeng and Huang, Zugui},
title = {GLP ‐1 receptor agonist liraglutide alleviates kidney injury by regulating nuclear translocation of NRF2 in diabetic nephropathy},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2024},
doi = {10.1111/1440-1681.70003}
}
EUVIMED